GLP 1 Agonists

This hub provides a comprehensive overview of GLP-1 receptor agonists, semaglutide, and related peptide therapeutics, integrating the latest scientific evidence and clinical perspectives. The linked articles examine the mechanisms of GLP-1–based therapies in weight loss, diabetes management, and beyond, as well as their emerging roles in addressing conditions such as alcohol addiction and menopause-related metabolic changes. Readers will find detailed discussions on efficacy, safety, patient selection, and the comparative potential of novel molecules like berberine. The collection also explores broader trends in peptide therapeutics and the future landscape of targeted treatment. This resource is designed for healthcare professionals, researchers, and individuals seeking authoritative, evidence-based information on GLP-1 and peptide-based interventions.

Do GLP-1 Drugs Reduce Cancer Risk or Increase It?

Emerging evidence links popular weight-loss drugs to lower cancer rates, but are these effects real, or simply a reflection of better metabolic health?

Overview

Explore authoritative articles on GLP-1, semaglutide, peptide therapeutics, weight loss, diabetes, and emerging treatments. This hub delivers evidence-based insights for clinicians, researchers, and anyone interested in targeted therapies.

Recent Advancements in Treatment for Parkinson’s Disease

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

The Potential of Peptide Therapeutics in Treating Chronic Diseases

Multiple Endocrine Neoplasia Type 1 (MEN1)

The Future of Diabetes Treatment

Are GLP-1 Drugs the Future of Alcohol Addiction Treatment?

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Is Berberine Really “Nature’s Ozempic”? What Science Says

Top Nutrients and Habits That Boost GLP-1 Naturally

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

How Does Semaglutide Work to Lose Weight?

See more featured articles »

How Oral GLP-1 Drugs Work For Weight Loss

Who Should Take Weight Loss Injections, and Who Shouldn’t?

The Impact of Glucagon on Diabetes Management

The Natural Molecule That Could Rival Ozempic

Semaglutide and Weight Loss in Menopause

Gut-Brain Axis and Obesity

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

What Are Advanced Glycation End Products and Why They Matter

The Unexpected Effects of GLP-1 Medications on Women’s Health

Wegovy: A Breakthrough in Weight Loss?

Peptide Therapy: The Future of Targeted Treatment?

Latest GLP 1 Agonists News and Research

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

People judge GLP-1 users more harshly than dieters

Stigma surrounding GLP-1 weight loss treatments reveals societal biases, impacting individuals' mental health and the effectiveness of obesity interventions.

7 May 2026

GLP-1 weight-loss drugs modulate brain reward circuits to suppress eating for pleasure

A National Institutes of Health (NIH)-funded study has found that an emerging class of GLP-1 weight-loss drugs suppress eating for pleasure, or hedonic feeding, in mice by modulating a reward circuit deep within the brain.

6 May 2026

Bariatric surgery offers greater long-term health protection for seniors than GLP-1 drugs

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

6 May 2026

Popular GLP-1 drugs significantly reduce major cardiovascular events,

Researchers evaluate the long-term cardiovascular safety and efficacy of GLP-1RAs in high-risk populations.

6 May 2026

Exercise remains essential alongside GLP-1 obesity treatments

As GLP-1 receptor agonists reshape obesity treatment, a new medical perspective published in the Journal of the American Medical Association, or JAMA, underscores a persistent gap in care: integrating exercise into weight management in ways patients can sustain.

5 May 2026

GLP-1 use surges as surgery rates drop for severe obesity

Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially -- from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 -- according to a new real-world analysis presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

GLP-1 drugs combined with surgery yield superior weight loss results

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery.

5 May 2026

A new tool that predicts obesity-related disease risk beyond BMI

OBSCORE is a data-driven tool that identifies high-risk individuals for obesity-related diseases, enhancing treatment targeting beyond traditional BMI metrics.

5 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

GLP-1 drugs reduce risk of major adverse cardiovascular events

New research has shown that GLP‑1 weight-loss drugs deliver protection against heart attacks, strokes and premature death over a sustained period of time.

30 Apr 2026

Obesity may leave immune cells stuck in inflammatory mode after weight loss

A new EMBO Reports study suggests that obesity can leave a lasting epigenetic imprint on CD4 T cells, delaying the restoration of adaptive immune balance after weight loss. Using mouse models and human cohorts, researchers linked this immune “memory” to DNA methylation changes, saturated fatty acids, autophagy, and immune senescence.

28 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

GLP-1 weight loss is driven mainly by fat loss, not muscle loss

GLP-1-based therapies helped adults with overweight or obesity lose weight mainly by reducing fat mass and visceral adipose tissue, while lean body mass losses were generally modest. The findings suggest these treatments can support higher-quality weight loss when paired with individualized care, nutrition, and resistance training.

27 Apr 2026

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).

23 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026

NHS grant funds study on the use of weight-loss drugs for treating PCOS

Dr. Shagaf Bakour, a gynecologist and director of medical education at Aston Medical School, has won an NHS research grant to investigate the use of weight-loss drugs in the treatment of polycystic ovary syndrome (PCOS).

21 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

AI analyzes Reddit posts to find underreported GLP-1 side effects

By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.

10 Apr 2026